|
Genentech’s incumbent Rituxan can expect a challenge from Cephalon’s Treanda |
Author: Jay Scouten
2010-01-20 |
Genentech’s incumbent Rituxan (rituximab) can expect a challenge from Cephalon’s Treanda (bendamustine) in treating Non-Hodgkin’s Lymphoma, according to ASH 2009 attendees’ clinical judgement
The results of the StiL Study released at ASH 2009 challenge the standard of care algorithm to add Cephalon’s Treanda (bendamustine) and by doing so, significantly increase patients’ median progression-free survival (PFS), a key indicator of chemotherapeutic efficacy
Standard of care regimens in Non-Hodgkin’s Lymphoma, called R-CHOP and R-ICE are Rituxan (rituximab)-based and used in 68% of patients... Read More
|
|
Uncle Walt reviews a Glucometer with an integrated USB connector. |
Author: Jay Scouten
2010-01-08 |
Even with easy notation of pre- or post-prandial readings, whether a patient’s feeling sick or stressed, Bayer’s recent foray into blood sugar measurements begs “What now?”
Even with a pile of great data, (watch for integration with MedTronic, et al’s continuous glucose monitor) there are no CPT or ICD-9 (maybe ICD-10?) codes for continuously monitoring glucose levels of 400 patients in near real-time, even if it were compatible with xHR systems from GE, Google or Microsoft... Read More
|
|
From the Know Your Respondents (KYR) Dept.: |
Author: Jay Scouten
2009-12-31 |
We marketing types are quick to encourage docs to participate in just about anything, and here’s another with which you’re probably already familiar: social networking
Not surprisingly, it’s a challenge to teach the old dogs which tricks are professionally appropriate, and which will make them the subject of a prime-time “Predator” exposé... Read More
|
|
Nanoshell |
Author: Jay Scouten
2009-12-31 |
Now, I wouldn’t want to spell Prognosis without a ‘g’
The freshly minted diagnostic field called “Theranostics” has no such qualm... Read More
|
